| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7204f5871ac07bc94ff734e87432ea0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed3c2f63a5b1c705b1b389a6f1f1f7c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df02dc2eab1779ebc7dfb5accf94318b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2020-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57c3bddda6bc7d4e5ea03164bd28d6ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_102c493762a677f2368df4092c79977b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af7966b11b71a40bc359b83e7b3afff4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae6ef3c0296667b7f806bb41479a7d41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7972fa98be80cdbfdfef387cf80242ac |
| publicationDate |
2021-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021043724-A1 |
| titleOfInvention |
Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia |
| abstract |
Acute myeloid leukemia (AML) are heterogeneous malignancies arising from the multistep transformation of bone marrow immature cells. The inventors showed that RAS pathway mutations were detected in 40% of FLT3- and NPM1-unmutated AML cases and correlated with higher white blood cell count, blast cell percentage and reduced survival after intensive therapy. Building on genetic models of RAS activation, they highlighted the leukemogenic potential of RAS pathway alterations, and the efficacy and limitations of MEK inhibitors in this context. From high-content chemical screens, the inventors unraveled pyrvinium pamoate – an anthelminthic drug approved in human patients – as displaying a preferential cytotoxicity against RAS activated cells. This potential clinical candidate demonstrated a robust synergistic activity with the MEK inhibitor trametinib, including in primary samples from AML patients. Together the data suggest that RAS pathway altered cases may represent a specific AML subtype, in which the anti-leukemic molecule pyrvinium pamoate may represent a new promising therapeutic strategy. |
| priorityDate |
2019-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |